Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 14/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21802040 | 0.90 | ALPL (0.44) | ALPLPOLBPTPN2PTPN1PTPN6 | |
| SCHEMBL21801977 | 0.88 | ALPL (0.51) | ALPLHTTOPRK1 | |
| SCHEMBL21802084 | 0.84 | ALPL (0.54) | ALPL | |
| SCHEMBL30538734 | 0.83 | ALPL (0.55) | ALPLOPRK1 | |
| SCHEMBL21801956 | 0.83 | ALPL (0.49) | ALPLHTT | |
| SCHEMBL21801957 | 0.83 | ALPL (0.49) | ALPLHTT | |
| SCHEMBL21802113 | 0.83 | ALPL (0.49) | ALPLHTT | |
| SCHEMBL21802103 | 0.81 | ALPL (0.48) | ALPLHTT | |
| SCHEMBL21802085 | 0.81 | ALPL (0.45) | ALPLOPRK1 | |
| SCHEMBL30538749 | 0.75 | ALPL (0.44) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | ALPL 7/4885POLB 4183/4885PTPN2 80/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | ALPL 5/4885POLB 4089/4885PTPN2 248/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | ALPL 7/4885POLB 4183/4885PTPN2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.